GD2-CART01

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 01:52, 25 June 2023 by Warner-admin (talk | contribs) (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study")
Jump to navigation Jump to search

Mechanism of action

CAR-T

Preliminary data

Neuroblastoma

  1. GD2CAR01: Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. link to original article PubMed Clinical Trial Registry